Haemonetics (HAE)
(Delayed Data from NYSE)
$76.43 USD
-9.29 (-10.84%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $76.38 -0.05 (-0.07%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth B Momentum A VGM
Price, Consensus and EPS Surprise
HAE 76.43 -9.29(-10.84%)
Will HAE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HAE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HAE
HAE or BSX: Which Is the Better Value Stock Right Now?
Haemonetics (HAE) Misses Q1 Earnings Estimates
HAE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 30.13% Upside in Haemonetics (HAE): Can the Stock Really Move This High?
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
Other News for HAE
Haemonetics Corporation (HAE) Q1 2025 Earnings Call Transcript
Haemonetics: A Stable Outlook with Promising Profitability Targets Justifies Buy Rating
Haemonetics Breaks Below 200-Day Moving Average - Notable for HAE
Haemonetics: Fiscal Q1 Earnings Snapshot
Haemonetics 1st Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website